Martingale Asset Management L P Relmada Therapeutics, Inc. Transaction History

Martingale Asset Management L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$16.5 - $30.34 $227,799 - $418,874	-13,806 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$16.72 - $26.99 $61,863 - $99,863	-3,700 Reduced 21.14%	13,806 $372,000
Q4 2021 Feb 11, 2022	SELL	$16.93 - $26.82 $1,693 - $2,682	-100 Reduced 0.57%	17,506 $394,000
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $220,786 - $351,177	10,100 Added 134.56%	17,606 $461,000
Q1 2021 May 13, 2021	SELL	$31.52 - $39.28 $3,152 - $3,928	-100 Reduced 1.31%	7,506 $264,000
Q4 2020 Feb 10, 2021	SELL	$29.88 - $39.8 $893,412 - $1.19 Million	-29,900 Reduced 79.72%	7,606 $243,000
Q3 2020 Nov 12, 2020	BUY	$34.42 - $43.78 $1.29 Million - $1.64 Million	37,506 New	37,506 $1.41 Million

8.29M

364K

46.5K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $8.58M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.